Major lessons learned from Zarxio’s US launch: the start of a biosimilar revolution

Author(s): Michael Sarshad, BSc, MBA

Introduction: Launched in 2015, Zarxio™ (filgrastim-sndz) was the first biosimilar to gain US Food and Drug Administration (FDA) approval. In contrast, the first biosimilar was launched in Europe in 2006. Objective: To identify key biosimilar sales and marketing trends and their drivers, this will enable best practices to be outlined for manufacturers looking to enter […]

Read more →